NASDAQ:VALN Valneva (VALN) Stock Forecast, Price & News $12.61 -0.39 (-3.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$12.20▼$12.9050-Day Range$9.45▼$13.3652-Week Range$9.07▼$33.76Volume15,048 shsAverage Volume7,571 shsMarket Capitalization$875.76 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Valneva MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside74.5% Upside$22.00 Price TargetShort InterestHealthy0.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.47) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.77 out of 5 starsMedical Sector676th out of 981 stocksBiological Products, Except Diagnostic Industry110th out of 159 stocks 3.2 Analyst's Opinion Consensus RatingValneva has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, Valneva has a forecasted upside of 74.5% from its current price of $12.61.Amount of Analyst CoverageValneva has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.03% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Valneva has recently decreased by 1.98%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldValneva does not currently pay a dividend.Dividend GrowthValneva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VALN. Previous Next 1.4 News and Social Media Coverage News SentimentValneva has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Valneva this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 2 people have added Valneva to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Valneva insiders have not sold or bought any company stock.Percentage Held by Insiders14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.83% of the stock of Valneva is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Valneva are expected to grow in the coming year, from ($0.47) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Valneva is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Valneva is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValneva has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Valneva (NASDAQ:VALN) StockValneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.Read More Receive VALN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter. Email Address VALN Stock News HeadlinesJune 7, 2023 | finance.yahoo.comVALNEVA - Declaration of shares and voting rights: May 31, 2023May 31, 2023 | finance.yahoo.comValneva Announces the Availability of Documentation for its Shareholder MeetingJune 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 31, 2023 | finance.yahoo.comValneva to Present and Hold Investor Meetings at Upcoming Conferences in JuneMay 30, 2023 | finance.yahoo.comValneva Files for Chikungunya Vaccine Authorization with Health CanadaMay 25, 2023 | msn.comLyme Vaccines Are Finally Coming, and They May Not Look Like You'd ExpectMay 23, 2023 | msn.comFrance stocks lower at close of trade; CAC 40 down 1.33%May 18, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Stock Price Down 5.1%June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 17, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Sees Strong Trading VolumeMay 15, 2023 | americanbankingnews.comValneva SE (NASDAQ:VALN) Short Interest UpdateMay 13, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Shares Gap Up to $12.10May 11, 2023 | marketwatch.com2030, Oral Vaccines Market ResearchMay 7, 2023 | news.yahoo.comRebound in travel helps vaccine maker Valneva post smaller-than-expected lossMay 6, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Price Target Cut to $22.00 by Analysts at HC WainwrightMay 6, 2023 | americanbankingnews.comHead-To-Head Review: Vigil Neuroscience (NASDAQ:VIGL) & Valneva (NASDAQ:VALN)May 4, 2023 | finance.yahoo.comVALNEVA - Declaration of shares and voting rights - April 30, 2023May 4, 2023 | finance.yahoo.comUPDATE 2-Rebound in travel helps vaccine maker Valneva post smaller-than-expected lossMay 4, 2023 | finance.yahoo.comValneva Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesApril 26, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Stock Price Up 4.2%April 19, 2023 | msn.comRutgers Is A Test Site For First-Ever Kids' Vaccine For Lyme DiseaseApril 15, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Shares Gap Down to $11.62April 6, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Trading 5.7% Higher April 6, 2023 | finance.yahoo.comVALNEVA - Declaration of shares and voting rights - March 31, 2023April 5, 2023 | americanbankingnews.comFinancial Contrast: Valneva (VALN) and Its RivalsApril 5, 2023 | marketwatch.comOral Vaccines Market 2023 Size and Forecast to 2031April 1, 2023 | americanbankingnews.comValneva (NASDAQ:VALN) Shares Gap Up to $10.03See More Headlines VALN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VALN Company Calendar Last Earnings3/23/2023Today6/07/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VALN CUSIPN/A CIK1836564 Webvalneva.com Phone33-2-28-07-37-10FaxN/AEmployees762Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.00 High Stock Price Forecast$22.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+70.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-150,960,000.00 Net Margins-38.20% Pretax Margin-40.08% Return on Equity-81.79% Return on Assets-21.22% Debt Debt-to-Equity Ratio0.41 Current Ratio1.48 Quick Ratio1.33 Sales & Book Value Annual Sales$380.73 million Price / Sales2.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book3.85Miscellaneous Outstanding Shares69,450,000Free Float59,093,000Market Cap$895.91 million OptionableNot Optionable Beta2.61 Key ExecutivesMr. Thomas Lingelbach (Age 59)Chairman of the Management Board, Pres & CEO Comp: $820.44kMr. Franck Grimaud MBA (Age 55)Director Gen., Chief Bus. Officer & Member of Management Board Comp: $514.52kMr. Frederic Jacotot (Age 57)VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board Comp: $403.84kDr. Juan-Carlos Jaramillo M.D. (Age 51)Chief Medical Officer & Member of the Management Board Comp: $562.34kMr. Peter Buhler (Age 51)CFO & Management Board Member Mr. Perry CelentanoInterim Chief Operating OfficerMs. Dipal PatelChief Commercial Officer & Member of Management BoardMr. Joshua Drumm Ph.D.VP of Investor RelationsMs. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsMr. Gerald StrohmaierVP of Human ResourceMore ExecutivesKey CompetitorsADMA BiologicsNASDAQ:ADMAREGENXBIONASDAQ:RGNXAllogene TherapeuticsNASDAQ:ALLOTwist BioscienceNASDAQ:TWSTImmaticsNASDAQ:IMTXView All Competitors VALN Stock - Frequently Asked Questions Should I buy or sell Valneva stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VALN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VALN, but not buy additional shares or sell existing shares. View VALN analyst ratings or view top-rated stocks. What is Valneva's stock price forecast for 2023? 3 Wall Street analysts have issued 1 year price targets for Valneva's shares. Their VALN share price forecasts range from $22.00 to $22.00. On average, they anticipate the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 70.5% from the stock's current price. View analysts price targets for VALN or view top-rated stocks among Wall Street analysts. How have VALN shares performed in 2023? Valneva's stock was trading at $12.72 at the beginning of the year. Since then, VALN shares have increased by 1.4% and is now trading at $12.90. View the best growth stocks for 2023 here. When is Valneva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our VALN earnings forecast. How were Valneva's earnings last quarter? Valneva SE (NASDAQ:VALN) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by $0.94. The company had revenue of $113.75 million for the quarter, compared to analyst estimates of $110.50 million. Valneva had a negative net margin of 38.20% and a negative trailing twelve-month return on equity of 81.79%. What guidance has Valneva issued on next quarter's earnings? Valneva issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $236.11 million-$279.04 million, compared to the consensus revenue estimate of $384.53 million. When did Valneva IPO? (VALN) raised $99 million in an initial public offering on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. served as the underwriters for the IPO. What is Valneva's stock symbol? Valneva trades on the NASDAQ under the ticker symbol "VALN." How do I buy shares of Valneva? Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Valneva's stock price today? One share of VALN stock can currently be purchased for approximately $12.90. How much money does Valneva make? Valneva (NASDAQ:VALN) has a market capitalization of $895.91 million and generates $380.73 million in revenue each year. The company earns $-150,960,000.00 in net income (profit) each year or ($2.46) on an earnings per share basis. How many employees does Valneva have? The company employs 762 workers across the globe. How can I contact Valneva? The official website for the company is valneva.com. The company can be reached via phone at 33-2-28-07-37-10 or via email at investors@valneva.com. This page (NASDAQ:VALN) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.